Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

Group 1 - The article discusses Axsome Therapeutics, Inc. (NASDAQ: AXSM) and its Q3 2024 earnings, where a "Hold" rating was given for the stock [2] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [2] - The author, Edmund Ingham, has extensive experience in biotech consulting, having covered over 1,000 companies in the biotech, healthcare, and pharma sectors [2]